New Launch6 Oct 2025, 04:33 pm
Zydus Lifesciences Ltd Receives Approval from Health Canada for Liothyronine Tablets
AI Summary
Zydus Lifesciences Limited has received a Notice of Compliance (NOC) from Health Canada for generic Liothyronine tablets 5 mcg and 25 mcg. The tablets, a synthetic form of the thyroid hormone T3, are primarily indicated for treating hypothyroidism. The manufacturing will take place at Zydus’ plant in Ahmedabad SEZ. Liothyronine tablets had annual sales of 10.9 million CAD in Canada (IQVIA MAT June 2025).
Key Highlights
- Zydus Lifesciences Ltd receives approval from Health Canada for Liothyronine tablets 5 mcg and 25 mcg
- Liothyronine tablets are a synthetic form of the thyroid hormone T3, primarily indicated for treating hypothyroidism
- The tablets will be manufactured at Zydus’ plant in Ahmedabad SEZ
- Liothyronine tablets had annual sales of 10.9 million CAD in Canada (IQVIA MAT June 2025)